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ABSTRACT
Background
Protease inhibitors (PIs) are associated with hypertriglyceridemia and atherogenic
dyslipidemia. Identifying HIV-1-infected individuals who are at increased risk of PI-related
dyslipidemia will facilitate therapeutic choices that maintain viral suppression while reducing
risk of atherosclerotic diseases. Apolipoprotein C-III (apoC-III) gene variants, which vary by race/
ethnicity, have been associated with a lipid profile that resembles PI-induced dyslipidemia.
However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with
plasma lipid levels in HIV-1-infected individuals, has not been reported.
Methods and Findings
A cross-sectional analysis of race/ethnicity, apoC-III/apoA-I genotypes, and PI exposure on
plasma lipids was performed in AIDS Clinical Trial Group studies (n¼626). Race/ethnicity was a
highly significant predictor of plasma lipids in fully adjusted models. Furthermore, in stratified
analyses, the effect of PI exposure appeared to differ across race/ethnicity. Black/non-Hispanic,
compared with White/non-Hispanics and Hispanics, had lower plasma triglyceride (TG) levels
overall, but the greatest increase in TG levels when exposed to PIs. In Hispanics, current PI
antiretroviral therapy (ART) exposure was associated with a significantly smaller increase in TGs
among patients with variant alleles at apoC-III-482, 455, and Intron 1, or at a composite apoC-
III genotype, compared with patients with the wild-type genotypes.
Conclusions
In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific
differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III
gene on the development of PI-related hypertriglyceridemia. Given the multi-ethnic
distribution of HIV-1 infection, our findings underscore the need for future studies of
metabolic and cardiovascular complications of ART that specifically account for racial/ethnic
heterogeneity, particularly when assessing candidate gene effects.
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The use of potent antiretroviral therapy (ART) in patients
with HIV-1 is associated with a cluster of metabolic
complications, including atherogenic dyslipidemia [1–3].
Analyses of data in 17,852 patients from the Data Collection
on Adverse Events of Anti-HIV Drugs study document class
effects of ART on lipid proﬁles, with dyslipidemias observed
most commonly in patients receiving protease inhibitors (PIs)
[4,5]. Lipid abnormalities on PIs are characterized by elevated
triglycerides (TGs), low high-density lipoprotein cholesterol
(HDL-c) and increased apolipoprotein (apo) B, containing
very low-density lipoprotein remnants and small low-density
lipoprotein particles [2,3,6,7]. Recent studies suggest that PI-
based ART is associated with an increased risk for athero-
sclerotic cardiovascular (CV) events [4,8,9] and has raised
concerns for a future epidemic of CV disease in HIV-1
patients for whom life-long ART may be required for control
of viral replication. Strategies that identify HIV-1 individuals
at increased risk of ART-related metabolic complications are
likely to facilitate rational decision making when selecting
ART regimens, as well as early use of appropriate preventive
CV therapies in those at greatest risk.
The pathophysiology of dyslipidemia in ART-treated HIV
patients is multi-factorial and involves drug effects on lipid
metabolism [2,10], insulin signaling and adipose tissue [11],
immunologic or viral factors [12], and host genetics [13–15].
Lipid abnormalities have been associated with almost all PIs,
but vary with speciﬁc PIs, and are most frequent in patients
taking ritonavir (RTV) or RTV-‘‘boosted’’ PI combination
regimens [5,16]. The direct effect of PIs on lipid metabolism is
evident by elevations in TG following short courses of
treatment in HIV-1-uninfected, healthy individuals [17–19].
PIs modulate both the production of apoB particles and their
clearance [2,10,20]. Notably, PI ART-related dyslipidemia
resembles that observed in familial combined hyperlipidemia
[21], suggesting a potential role for variation in lipoprotein
genes that have been linked to this relatively common
inherited dyslipidemia [22].
ApoC-III is a 79-amino-acid protein whose plasma levels
are directly correlated with TGs in the general population
[23]. Although the in vivo function of apoC-III is poorly
understood [24], in vitro studies and gene manipulation in
mouse models have implicated apoC-III in regulating lipolysis
of TG-rich lipoprotein [25], and in modulating remnant
particle clearance by the liver [26,27]. Several studies have
established a complex interaction of genetic variation within
apoC-III, and the apoA-I/C-III/A-IV/AV cluster, with plasma
TG levels [24,28–30]. Recently, two groups reported a marked
increase in plasma TGs in HIV-1-infected patients on PI ART
regimens when they also carried a combination of apoC-III
and apoE gene variants [13,15], although these studies were
restricted almost entirely to Caucasians.
Despite a well-described relationship of race/ethnicity with
lipoproteins in the general population [31–33], there has been
little consideration of ethnicity in the development of
metabolic complications in HIV-1-infected individuals. Such
differences may be of speciﬁc relevance in ART-associated
dyslipidemia given the multi-ethnic distribution of HIV-1
infection and evidence for ethnic differences in linkage
disequilibrium (LD) patterns for several lipoprotein genes
[34–36]. We hypothesized that ethnic LD patterns in apoC-III
[36–38], as well as distinct susceptibility/resistance alleles for
lipid abnormalities [28–30,39], and prior evidence for mod-
iﬁcationof apoC-IIIeffects byethnicity [38,40],would resultin
differences across racial/ethnic stratum in the association of
apoC-III and ART with plasma lipids in HIV-1 infection.
We describe results of analyses from an ongoing project
designed to identify candidate genes that place ART-treated
HIV-1-infected individuals at higher risk of developing
dyslipidemia. As a primary hypothesis, we aimed to determine
whether race/ethnicity is a signiﬁcant predictor of plasma
lipids and ART-associated lipid abnormalities in HIV-1-
infected individuals and whether apoC-III/apoA-I gene
variants interacted with PI exposure to predict increased
plasma TGs within race/ethnicity strata.
Methods
Study Participants
As part of New Work Concept Sheet (NWCS) 224, we
performed a cross-sectional analysis of 626 HIV participants
enrolled in selected AIDS Clinical Trial Group (ACTG)
studies (28% from A5005s, 11% from A5068, 18% from
A5087, 19% from ACTG 372, and 23% from A5116) who also
had consented to collection and storage of their blood for
genetic studies (A5128). ACTG studies were approved by local
institutional review boards at each institution where partic-
ipants were recruited and all participants gave written
informed consent. These speciﬁc ACTG studies were selected
because appropriate data, including fasting plasma lipids and
DNA samples, were available and all participants were on
ART at time of sampling. Study A5005s was the metabolic
sub-study of ACTG 384, a six-arm comparison of three- or
four-drug ARTs with zidovudine and lamivudine, or stavu-
dine and didanosine, combined with efavirenz (EFV), nelﬁ-
navir (NFV), or both, in ART-naı ¨ve individuals [41]. ACTG
5068 compared two strategies, treatment interruption and
vaccination with ALVAC vCP1452, to augment HIV-speciﬁc
immune responses in individuals on stable ART. Protocol
A5087 enrolled ART-treated participants with dyslipidemia
who were randomized to one of two lipid-lowering inter-
ventions. ACTG 372 was a rollover study for ACTG 320 to
compare individuals receiving abacavir or a placebo in
combination with zidovudine, lamivudine, and indinavir.
Finally, A5116 was a class-sparing and regimen-simpliﬁcation
study for patients with advanced HIV disease. A more
detailed description of the above mentioned studies can be
found at http://www.clinicaltrials.gov. In our analysis, fasting
lipids were recorded in all patients in A5087 prior to starting
lipid-lowering therapy. Fasting lipids were recorded for
patients in A5005 at least 32 wk after start of ART, and for
all other studies at entry. Because lipid levels prior to HIV
therapy were not consistently available, our study represents
an analysis of treatment lipids across these ACTG studies.
Among study participants, n¼440 were on stable PI ART (n
¼398 on a non-RTV regimen) (and n¼42 on a RTV regimen;
median exposure 976 d; interquartile ranges [IQR] ¼ 244,
1245) or non-PI ART (n ¼ 131; 78% EFV and 13% NFV-
containing regimens). Patients with short exposure to PI ART
(,90 d; n ¼ 13), patients not currently on PIs but who were
exposed to a PI within 30 d (n ¼ 2), and patients with
unknown durations of exposure (n ¼ 40) were excluded from
analysis assessing PI effects.
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Study participants were evaluated through their respective
ACTG protocols. Demographic and clinical information was
provided to the NWCS224 team in a blinded, de-linked
manner from the Statistical and Data Analysis Center of the
Center for Biostatistics and AIDS Research at the Harvard
School of Public Health. Race/ethnicity data were self-
reported in these ACTG studies with race categorized as
Black, Caucasian, American Indian, Alaska Native, Native
Hawaiian, other Paciﬁc Islander, or Asian; and ethnicity as
Hispanic or non-Hispanic. For the purpose of our analysis, a
single three-level race/ethnicity variable was deﬁned, which
represented 97.6% of the full sample: White/non-Hispanic
(White), Black/non-Hispanic (Black), or Hispanic. Clinical
information collected included medical histories, concom-
itant medications, ART history, CD4 counts, viral loads,
height, weight, fasting plasma lipoproteins (TG, HDL-c, total
cholesterol), and glucose. Fasting plasma lipids were measured
according to the speciﬁc parent ACTG protocols. Non-HDL-c
was calculated by subtracting HDL-c from total cholesterol.
For the measured lipid data, .97% was conﬁrmed to have
been taken in the fasting state, the other ,3% were presumed
to be fasting based on study speciﬁc criteria. Body mass index
was calculated as weight divided by height squared.
Genotyping
DNA samples were isolated from blood (PUREGENE blood
kits; Gentra Systems, Minneapolis, Minnesota, United States)
at the ACTG DNA core laboratory at Vanderbilt University,
Nashville, Tennessee, United States. We genotyped six single
nucleotide polymorphisms (SNPs) in the apoC-III/apoA-I
cluster, ﬁve in apoC-III ( 482C/T [rs2854117],  455T/C
[rs2854116], intron 1 (466)G/C [rs2070669], Gly34Gly C/T
[rs4520], and exon 4 SstI 3238(5)C/G [rs5128]), and one in
apoA-I (XmnI;  2500C/T; chromosome position 11626561,
May 2004 assembly [http://www.genome.ucsc.edu]). SNPs were
chosen based on prior knowledge of association with plasma
lipoproteins (apoC-III-482C/T,  455T/C, SstI 3238C/G, and
apoA-I-2500C/T) [24,28–30] and to provide additional in-
formation of LD across apoC-III in these analyses (intron 1 G/
C and Gly34Gly in apoC-III). Genotyping was performed at
Penn Genotyping Core employing Taqman (Applied Bio-
systems, Foster City, California, United States) ABI SNP
genotyping assays were performed using the ABI 7900HT.
Statistical Analysis
Analyses were performed using Splus for Windows, Version
6.2 and R, version 2.0. Demographic and clinical character-
istics are given overall and by speciﬁc ACTG study. Data are
reported as medians and IQR for continuous variables, and as
proportions for categorical variables. Raw lipoprotein data
are presented by race/ethnicity, gender, and drug exposures.
Log transformations were employed to normalize lipoprotein
data for the purpose of modeling.
As a ﬁrst step, we assessed the main effects of race/ethnicity
and PI exposure on plasma lipids, using multiple linear
regression modeling. As a primary analysis, models were
ﬁtted treating PI exposure as a three-level factor (no current
PI exposure, currently exposed to a non-RTV–containing PI
regimen, and currently exposed to a RTV-containing
regimen). An analysis of PI exposure as an indicator for any
current PI use was also performed. Fully adjusted multi-
variable models included race/ethnicity, ART exposures
(current use of PI, stavudine, EFV, and NFV), age, gender,
study, CD4 count, and use of lipid-lowering therapy.
Maximum likelihood coefﬁcient estimates (reported as
estimated fold increases in each lipid outcome on the un-
logged scale), 95% conﬁdence intervals (CI) for the true
effects, and F-test statistics are reported. In addition, separate
multivariable models were ﬁtted for each SNP to assess their
independent main effects on lipid outcomes. SNPs were
coded as binary indicators for the presence of at least one
variant allele (i.e., heterozygous or homozygous rare.)
Although useful for comparison with published studies, a
notable limitation of this ﬁrst step is that it does not account
for potential interaction between race/ethnicity, PI exposure,
and genotypes.
We performed all subsequent analyses stratiﬁed by race/
ethnicity in order to address our primary hypothesis of an
interaction between genotype and PI exposure on TGs within
racial/ethnic stratum. Maximum likelihood estimates and
95% CIs for main effects of PI exposure and interaction
effects between PI exposure and apoC-III/apoA-I SNPs were
estimated within race/ethnicity stratum, based on fully
adjusted multivariable linear regression models. In these
models, PI exposure was treated as a two-level indicator for
any current exposure because there is no mechanistic data to
support differential interaction effects of apoC-III genotypes
with distinct PIs. Estimated fold increases in TGs and
corresponding 95% CIs on the un-logged scale are again
reported and signiﬁcance is based on a two-sided Wald test at
the 0.05 level. Predicted TG levels and 95% CIs, based on
these fully adjusted multivariable models, are provided for
non-PI and PI groups within racial/ethnic stratum, with and
without further stratiﬁcation by genotype.
Due to the high degree of concordance among the
observed apoC-III SNPs, an additional composite genotype
analysis is presented. As a primary analysis, the three apoC-III
SNPs described by Tarr et al. ( 482, 455, and SstI [3238]) [15]
were considered, and a new binary variable for the presence
of one or more variant allele at any number of these three
SNPs was created. The interaction between this composite
genotype variable and PI exposure was assessed within racial/
ethnic stratum as described above for the single SNP PI
interaction. Although power for three-way interactions was
limited, the interaction of individual SNPs and the composite
genotype, with race/ethnicity and PI exposure was estimated
and tested for completeness.
Estimation of apoC-III haplotype frequencies within race/
ethnic strata and the assessment of whether these haplotypes
modiﬁed the effects of PI exposure on TGs, was performed
using the R functions haplo.em and haplo.glm in the
haplo.stats library as described by Lake et al. [42]. This
approach allows for estimating and testing interaction effects
between haplotypes and PI exposure when linkage phase is
ambiguous and employs an expectation-maximization type
algorithm that iterates between estimating haplotype prob-
abilities and estimating regression parameters.
Sample Size Considerations
The sample size provides greater than 80% power to detect
moderate PI genotype interaction effect sizes of 0.23, 0.36,
and 0.35 within Whites, Blacks, and Hispanics, respectively,
using a two-sided level ¼ 0.05 test, and within-cell respective
PLoS Medicine | www.plosmedicine.org March 2006 | Volume 3 | Issue 3 | e52 0339
Ethnicity, ApoC-III, and Lipids in HIVassumed standard deviations of 0.7, 0.5, and 0.6 based on
observed data (NCSS 2001 PASS 2000.) Notably, our analysis
is not able to rule out smaller underlying interaction effects.
Results
Demographic and clinical information by study are
provided in Table S1. Median age of the cohort was 41
(IQR: 36 to 48), 89% were male, and 39 patients were on lipid-
lowering therapies. Median CD4 was 442 (IQR: 294.3 to 642.8)
and 91.1% of patients had RNA copies ,400. The proportion
of Black participants (19.3%) was somewhat lower than that
enrolled in all ACTG studies (27%) or receiving HIV care
(33%) [43], but overall gender, race, and age distributions in
our study sample were consistent with population estimates
for ART-treated HIV adults in the United States. As expected
from ACTG study-speciﬁc criteria, a number of character-
istics, including type of ART, race/ethnicity, use of lipid-
lowering therapy, and lipid levels, differed across studies,
underscoring the need to control for potential confounding
by study.
Summaries of lipid outcomes by race/ethnicity and gender
are presented in Table 1. Black participants tended to have
lower TGs and non-HDL-c and higher HDL-c than Whites
and Hispanics. As expected, participants on any number of
PIs (compared to those not on PIs) tended to have higher TGs
and non-HDL-c. Consistent with previous reports [5,15], the
most abnormal lipid proﬁles were observed for participants
on RTV-containing PI regimens.
Association of Race/Ethnicity, PI Exposure, and ApoC-III/
ApoA-I Genotypes with Plasma Lipids
Race/ethnicity was a highly statistically signiﬁcant predictor
of plasma lipids even after controlling for gender, study, age,
CD4 count, use of lipid-lowering therapy, and ART drug
exposure (Table 2). Overall, Blacks had lower TG and non-
HDL-c and higher HDL-c than Whites and Hispanics in fully
adjusted models. PI exposure was also a signiﬁcant predictor
of TGs and non-HDL-c with participants receiving RTV-
containing PI therapy having an estimated 1.46-fold greater
TG levels and 1.25-fold greater non-HDL-c levels compared
with participants receiving non-PI therapies. There were no
signiﬁcant associations between individual apoC-III/apoA-I
SNPs and plasma lipids in fully adjusted models (Table S2.)
Overall, these analyses are limited due to potential for
differential PI effects on lipids across racial/ethnicity and the
modifying effects of apoC-III/apoA-I genotypes on PI
association with lipids.
Modification of PI Effects on Plasma TG by Race/Ethnicity
As illustrated in Figure 1, current exposure to non-RTV-
and RTV-containing PI regimens (compared to no current PI
exposure), without consideration for genotypes, tended to be
associated with higher TGs, and the strength of this
association varied across race/ethnicity. Of note, non-RTV–
containing PI regimens were associated with increased
plasma TGs in Black/non-Hispanics (estimated fold increase
¼1.39, 95% CI¼[1.02, 1.89]). This trend was also observed in
Hispanics (estimated fold increase ¼ 1.23, 95% CI ¼ [0.89,
1.69]), but not in Whites (estimated fold decrease¼0.97, 95%
CI ¼ [0.80, 1.18]). RTV-containing PI therapy appears to be
associated with even greater increases in TGs within all racial/
ethnic groups, though the within-strata numbers of partic-
ipants on RTV are small.
Modification of PI Effects on Plasma TG by ApoC-III/ApoA-I
Genotypes within Race/Ethnic Strata
Genotype frequencies varied markedly across race/ethnic-
ity (Table S3). For example, 53.4% of Whites had the apoC-
III-482CC genotype, while only 8.3% of Blacks and 35.7% of
Hispanics had this genotype. Similar race/ethnicity-speciﬁc
differences were seen for apoC-III, 455, and apoC-III Intron
1. After stratifying by race/ethnicity, tests of departures from
Hardy-Weinberg Equilibrium were not signiﬁcant for any of
the SNPs (unpublished data). The estimated haplotype
frequencies (given in Table 3) varied similarly across race/
ethnicity with the ‘‘wild-type’’ haplotye ( 482C, 455T, Intron
1G, Gly34GlyC, 3238C) frequency estimated at 45.5% in
Whites, 10.8% in Blacks, and 35.1% in Hispanics.
Table 4 illustrates the interactions between PI exposure
and each of the six SNPs in apoC-III/apoA-I on TG levels
within race/ethnicity strata. The effect of PI exposure on TG
Table 1. Lipid Profiles by Race/Ethnicity, Gender, and PI Exposure
Category Characteristic Median (IQR)
TGs (mmol/l) HDL-c (mmol/l) Non-HDL-c (mmol/l)
Full sample (n ¼ 626) 2.1 (1.3, 2.6) 1.0 (0.8, 1.2) 4.4 (3.5, 5.4)
Race/ethnicity White/non-Hispanic (n ¼ 378, 60.4%) 2.3 (1.4, 3.9) 1.0 (1.1, 1.4) 4.6 (3.7, 5.6)
Black/non-Hispanic (n ¼ 121, 19.3%) 1.6 (1.0, 2.4) 1.1 (0.9, 1.4) 3.8 (3.0, 4.8)
Hispanic (n ¼ 112, 17.9%) 2.7 (1.5, 3.8) 1.0 (0.9, 1.1) 4.6 (3.7, 5.5)
Other (n ¼ 15, 2.4%) 2.1 (1.3, 2.0) 0.8 (0.8, 0.9) 3.8 (3.5, 4.8)
Gender Male (n ¼ 557, 89.0%) 2.1 (1.3, 3.8) 1.0 (0.8, 1.2) 4.4 (3.5, 5.4)
Female (n ¼ 69, 11.0%) 1.7 (1.1, 2.8) 1.2 (1.0, 1.4) 4.3 (3.7, 5.4)
Drug exposure
a Not on any PIs (n ¼ 131, 20.9%) 1.8 (1.2, 2.9) 1.0 (0.8, 1.2) 3.8 (3.3, 5.1)
Any number of PIs
b (n ¼ 440, 70.3%) 2.2 (1.3, 3.8) 1.0 (0.8, 1.2) 4.6 (3.8, 5.6)
Non-RTV-containing PI therapy (n ¼ 398, 63.6%) 2.1 (1.3, 3.5) 1.0 (0.8, 1.2) 4.4 (3.7, 5.4)
RTV-containing therapy
c (n ¼ 42, 6.7%) 4.2 (3.0, 6.3) 0.9 (0.8, 1.2) 6.4 (5.5, 7.2)
an¼55 participants were removed from analysis of drug exposure due to short durations of exposure (currently on a PI but for less than 90 d, n¼13), short PI washout periods (not currently on a PI but exposed within the last 30 d, n¼2) or
missing information (drug histories or durations were not available, n ¼ 40).
bn ¼ 37 participants were on RTV-boosted therapy and an additional 33 participants were receiving non-RTV-containing dual PIs: nelfinavir and either indinavir, (n ¼ 26), aprenavir (n ¼ 5), or saquinavir (n ¼ 2).
cn ¼ 5 of these participants were on RTV alone, n ¼ 4 participants were on three PIs and the remaining participants were on two PIs.
DOI: 10.1371/journal.pmed.0030052.t001
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Hispanics. As an illustration, the effect of PI exposure for
Hispanic participants with no variant alleles at apoC-II-482
was to increase TGs 1.79-fold, while the effect of PI exposure
for Hispanic participants with one or more variant alleles at
apoC-III-482 was to decrease TGs 0.97-fold ( ¼ 1.79 3 0.54).
Predicted TG levels by race/ethnicity, PI exposure, and
genotype are given in Table 5 and provide an illustration of
these interaction effects.
A signiﬁcant difference in the effect of PI exposure on TGs
across genotypes in Whites and in Blacks was not detectable.
However, predicted TG levels across genotypes did differ
across the three ethnic groups (Table 5), suggesting race-
speciﬁc differences in the inﬂuence of apoC-III genotypes on
PI-related dyslipidemia. The difference in predicted TGs
between PI-exposed and unexposed Hispanic participants
with the apoC-III-482 CC genotype compared to participants
with the CT/TT genotype (þ 0.8 mmol/l versus  0.1 mmol/l)
appears to be different from that in Whites ( 0.1 mmol/l
versus þ 0.3 mmol/l) and Blacks ( 0.4 mmol/l versus þ 0.3
mmol/l). Thus, in contrast to Hispanics, PI exposure tended to
be associated with higher TGs in Whites and Blacks with the
 482 CT/TT genotypes, but not in those with the CC
genotype. In fully adjusted models that combined racial/
ethnic groups, the three-way interaction effects between PI
use, SNPs, and Hispanic race/ethnicity were marginally
signiﬁcant for apoC-III-482 (p ¼ 0.07), apoC-III-455 (p ¼
0.08), apoC-III Intron 1 (p¼0.03), and apoA-I XmnI ( 2500T/
C) (p ¼ 0.06).
Modification of PI Effects on Plasma TG by Composite
ApoC-III Genotypes within Race/Ethnic Strata
The tests of interaction between each SNP and PI exposure
are not independent due to the high degree of concordance
across genotypes: n ¼ 96 out of 104 (92.3%) Hispanics were
concordant in their genotypes for  482 and  455 (i.e., they
were wild-type for both or variant for both based on the
binary SNP coding); n ¼ 99 of 104 (95.2%) were concordant
for  482 and Intron 1; and n ¼ 92 of 104 (88.5%) were
concordant for all three SNPs.
Consistent with the single SNP analysis, there appears to be
a protective effect of the composite variant genotype, (apoC-
III  384,  355, and SstI [3238]) on the association of PIs with
TG levels within Hispanics (interaction effect ¼ 0.56, 95% CI
¼ [0.32, 0.97], p-value ¼ 0.04). Among Hispanic participants
with no variant alleles at the three apoC-III SNPs indicated (n
¼ 72), PI exposure (n ¼ 57) was associated with 1.89-fold
higher plasma TG levels compared to the non-PI–exposed
group (n ¼ 15); however, among Hispanic participants with a
variant allele at one or more of the three apoC-III SNPs
indicated (n ¼ 32), the increase in TGs in PI-exposed
participants (n ¼ 23) versus non-PI–exposed subjects (n ¼ 9)
was only 1.06-fold (Figure 2). Similar to the single SNP
analysis, the three-way interaction between PI use, genotype,
and race/ethnicity was marginally signiﬁcant (0.055) with an
estimated fold decrease of 0.52. Analyses did not reveal
signiﬁcant haplotype PI-interaction effects on TGs. However,
within Hispanics, the interaction effects of the non-wild-type
haplotypes with PI exposure were 0.84- and 0.75-fold
decreases for additive or dominant models respectively,
which is consistent with the direction and magnitude of
effects observed for composite genotypes and individual SNP
analyses.
Discussion
Our study is the ﬁrst of race/ethnicity inﬂuences on plasma
lipoproteins and is the largest study of genetic effects on
lipids in HIV-1-infected patients. We found that race/
ethnicity was a predictor of plasma lipids in HIV-1 patients
on ART. Overall, Black patients on ART had a less
atherogenic lipid proﬁle compared to Whites and Hispanics.
This ﬁnding is consistent with epidemiological data in non-
HIV-1 populations [31–33], but may be of particular
importance given the worldwide demographics of HIV-1
infection. Despite lower plasma lipids, the effect of PI
exposure on TGs was most marked in Blacks, and, in fact,
the effect of non-RTV PI therapy appeared to be stronger in
both Blacks and Hispanics compared to Whites. We also
found a signiﬁcant difference in the inﬂuence of apoC-III
genotypes and PI use across ethnic groups in the association
with TGs. Hispanic patients with individual apoC-III variant
Table 2. Multivariable Adjusted Association of Race/Ethnicity and PI Exposure with Lipid Outcomes
Category Characteristic Model Estimate of Fold Change in Lipid Value (95% CI)
TGs (mmol/l) HDL (mmol/l) Non-HDL-c (mmol/l)
Race/ethnicity
a Black /non-Hispanic 0.78 (0.68, 0.90)
b 1.14 (1.07, 1.22)
b 0.89 (0.84, 0.94)
b
Hispanic 1.09 (0.95, 1.25) 1.01 (0.50, 1.06) 1.0 (0.94, 1.06)
Overall F test for effect of race/ethnicity 8.46 (df ¼ 2, 537); p , 0.001 8.40 (df ¼ 2,496); p , 0.001 7.70 (df ¼ 2, 495); p , 0.001
PI
c Non-RTV-containing PI therapy 1.10 (0.95, 1.27) 1.03 (0.96, 1.10) 1.15 (1.08, 1.23)
b
RTV-containing PI therapy 1.46 (1.15, 1.86)
d 1.09 (0.97, 1.21) 1.25 (1.13, 1.39)
b
Overall F test for effect of PI 4.83 (df ¼ 2, 537); p ¼ 0.008 1.06 (df ¼ 2,496)
c; p ¼ 0.35 12.98 (df ¼ 2, 495); p , 0.001
Models are fully adjusted for gender, study, age, CD4 count, use of lipid-lowering therapy, ART drug exposure (indicators for stavudine, EFV, NFV), PI exposure (three-level factor), and race/ethnicity (three-level factor). Participants missing any
of these variables and participants with uncertain PI exposure were excluded from analysis. Individual apoC-III genotypes were not significant predictors for lipid outcomes (p . 0.05, given in Table S3) and controlling additionally for apoC-III
genotypes did not alter the coefficient estimates substantially, though the effect of Black/non-Hispanic was slightly attenuated on all outcomes.
aParticipants who are not White, Black, or Hispanic were excluded from analysis and White was treated as reference.
bIndicates significance at the 0.001 level.
cNo current PI exposure was treated as reference.
dIndicates significance at the 0.05 level.
Note: models were fit based on natural log transformed lipid levels and resulting coefficient estimates were exponentiated; therefore, reported effects can be interpreted as fold increases or percent change in lipid values for the corresponding
predictor compared to the referent group. For example, Black participants had 22% lower TGs and 14% higher HDL-c compared to Whites. In a similar model, where PI exposure was coded as a binary variable, any PI exposure (n ¼ 440),
compared to no PI exposure, was associated with a 1.14- (0.98, 1.32) fold increase in TG (Wald test p ¼ 0.08), 1.04- (0.97–1.11) fold change in HDL-c (p ¼ 0.31), and a 1.17- (1.10–1.24) fold increase in non-HDL-c (p , 0.001).
DOI: 10.1371/journal.pmed.0030052.t002
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Ethnicity, ApoC-III, and Lipids in HIValleles, or across a composite apoC-III genotype, had lower
TGs than patients with the wild-type genotypes when on PI
therapy. This interaction was not observed in Whites and
Blacks. Overall, these results provide evidence for race-
speciﬁc differences in both the occurrence of dyslipidemia on
ART as well as in the inﬂuence of genetic factors on the
prevalence of PI-related lipid abnormalities.
Linkage and association studies have established a relation-
Figure 1. Predicted TG Levels for PI- and Non-PI–Exposed Individuals by Race/Ethnicity
Estimated fold increases (95% CI) for non-RTV–containing PI regimen (compared to no current PI exposure) are 0.97 (0.80, 1.18) for White/non-Hispanics,
1.39§ (1.02, 1.89) for Black/non-Hispanics, and 1.23 (0.89, 1.69) for Hispanics. Estimated fold increases (95% CI) for RTV-containing PI regimen (compared
to no current PI exposure) are 1.35§ (1.00, 1.83) for White/non-Hispanics, 1.62 (0.75, 3.50) for Black/non-Hispanics, and 1.51 (0.91, 2.52) for Hispanics. §
Indicates significantly different than 1.0-fold at the 0.05 level.
DOI: 10.1371/journal.pmed.0030052.g001
Table 3. Estimated ApoC-III Haplotype Frequencies by Race/Ethnicity
ApoC-III Haplotype Estimated
a Frequency
b (%)
 482  455 Intron I Gly34Gly SstI (3238) Whites/Non-Hispanic Blacks/Non-Hispanic Hispanic
C T G C C 45.5 10.8 35.1
C C G C C 12.1 1.5 4.5
C T G T C 10.5 6.3 17.6
T C C C C 12.4 57.1 20.1
T C C T G 8.2 7.1 16.5
aEstimation is based on an expectation-maximization algorithm and implemented using the haplo.em function of the haplo.stats library in R.
bEstimated frequencies greater than 10% in at least one race/ethnicity group are reported.
DOI: 10.1371/journal.pmed.0030052.t003
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Ethnicity, ApoC-III, and Lipids in HIVship of apoC-III genotypes, and the apoA-I/CIII/AIV/AV gene
cluster, with alterations in plasma TGs [23,28,29,39,44,45].
However, little is known of the molecular mechanisms [24].
The concurrence of SNPs in these linked genes complicates
the assignment of metabolic effects to individual variants. For
example, most [46,47] evidence suggest that two apoC-III
promoter SNPs ( 482C/T and  455T/C) attenuate the
inhibitory action of insulin on apoC-III gene expression
and inﬂuence plasma lipids [46,48]. However, almost all
studies suggest that these SNPs are associated with lipid levels
through their LD with the well studied 39 UTR SstI (3238)
variant [29,30,49,50], which may, in turn, be associated with
TG levels through LD with variants elsewhere in the cluster
[39,45]. In fact, apoA-I/CIII/AIV/AV SNP and haplotype
frequencies vary markedly across ethnic groups [36–38], but
most studies of the gene cluster have been restricted to
Whites. Furthermore, several environmental factors [51–54],
including race/ethnicity [38,40], appear to modify the impact
of apoC-III variation on lipids and metabolic traits. For
example, in a tri-ethnic sample (n ¼ 1,366) Waterworth et al.
Table 4. Interaction Effects of Variants in ApoC-III /ApoA-I with PI on Plasma TG by Race/Ethnicity
Model Characteristic
a Estimated Fold Increase in TGs (mmol/l) (95% CI)
White/Non-Hispanic Black/Non-Hispanic Hispanic
ApoC-III-482 C/T PI 0.92 (0.70, 1.21) 0.78 (0.34, 1.81) 1.79 (1.16, 2.77)
Variant (CT/TT) 0.85 (0.63, 1.15) 0.74 (0.35, 1.57) 1.45 (0.89, 2.35)
PI 3 variant 1.23 (0.87, 1.73) 1.97 (0.82, 4.73) 0.54 (0.31, 0.94)
b
ApoC-III-455 T/C PI 0.94 (0.70, 1.28) 0.77 (0.34, 1.78) 1.87 (1.15, 3.03)
Variant (TC/CC) 0.86 (0.63, 1.18) 0.73 (0.34, 1.53) 1.39 (0.86, 2.25)
PI 3 variant 1.09 (0.77, 1.56) 2.00 (0.84, 4.77) 0.56 (0.33, 0.97)
b
ApoC-III Intron 1 G/C PI 0.93 (0.70, 1.22) 0.81 (0.25, 2.68) 1.77 (1.15, 2.71)
Variant (GC/CC) 0.92 (0.68, 1.23) 0.76 (0.27, 2.14) 1.45 (0.86, 2.25)
PI 3 variant 1.21 (0.87, 1.69) 1.80 (0.53, 6.09) 0.55 (0.33, 0.97)
b
ApoC-III Gly34Gly C/T PI 0.96 (0.74, 1.23) 1.37 (0.93, 2.01) 1.41 (0.94, 2.12)
Variant (CT/TT) 0.92 (0.70, 1.22) 0.95 (0.62, 1.44) 1.09 (0.68, 1.73)
PI 3 variant 1.14 (0.82, 1.28) 1.05 (0.65, 1.72) 0.78 (0.45, 1.35)
ApoC-III SstI (3238C/G) PI 1.00 (0.80, 1.24 ) 1.39 (1.00, 1.91) 1.41 (0.98, 2.03)
Variant (CG/GG) 0.93 (0.65, 1.33) 0.89 (0.55, 1.45) 1.23 (0.75, 2.01)
PI 3 variant 1.15 (0.77, 1.73) 1.08 (0.62, 1.90) 0.69 (0.39, 1.21)
ApoA-I XmnI ( 2500C/T) PI 1.01 (0.81, 1.24) 1.43 (0.97, 2.12) 1.42 (0.98, 2.05)
Variant (CT/TT) 0.84 (0.58, 1.22) 1.20 (0.79, 1.81) 1.32 (0.77, 2.25)
PI 3 variant 1.08 (0.72, 1.64) 0.99 (0.61, 1.60) 0.67 (0.37, 1.23)
aPI is defined as an indicator for current exposure to at least one PI and Variant is defined as an indicator for the presence of at least one variant allele. Models are fit separately for each SNP and adjusted for sex, study, age, CD4 count, use of
lipid-lowering therapy, and ART drug exposure (indicators for stavudine, EFV, and NFV).
bIndicates presence of a significant interaction effect at the 0.05 level based on a Wald test. Observations missing genotype information were excluded from corresponding model (n¼8 for apoC-III-482, n¼5 for apoC-III-455, n¼6 for apoC-III
Intron 1, n ¼ 2 for apoC-III Gly34Gly, n ¼ 3 for apoC-III SstI [3238], and n ¼ 8 for apoA-I XmnI [-2500]).
Note: models were fit based on natural log transformed lipid levels and resulting coefficient estimates were exponentiated; therefore, reported effects can be interpreted as fold increases (decreases) in lipid values for the corresponding
predictor compared to the referent group.
DOI: 10.1371/journal.pmed.0030052.t004
Table 5. Predicted TG Levels by Genotype, Race/Ethnicity, and PI Exposure
Model Genotype Predicted TG Levels (mmol/l) (95% CI)
Whites/Non Hispanic Blacks/Non-Hispanic Hispanic
Non-PI PI Non-PI PI Non-PI PI
Overall 1.8 (1.4, 2.2) 1.8 (1.4, 2.3) 1.1 (0.7, 1.5) 1.5 (1.1, 2.1) 1.3 (0.9, 2.0) 1.7 (1.1, 2.6)
ApoC-III-482 C/T CC 1.9 (1.5, 2.5) 1.8 (1.4, 2.3) 1.5 (0.6, 3.3) 1.1 (0.7, 1.9) 1.0 (0.6, 1.7) 1.8 (1.2, 3.0)
CT/TT 1.6 (1.2, 2.2) 1.9 (1.4, 2.4) 1.1 (0.7, 1.5) 1.6 (1.1, 2.4) 1.5 (0.9, 2.4) 1.4 (0.9, 2.3)
ApoC-III-455 T/C TT 1.9 (1.4, 2.6) 1.8 (1.4, 2.4) 1.5 (0.7, 3.3) 1.1 (0.7, 1.9) 1.0 (0.6, 1.8) 1.9 (1.2, 3.1)
TC/CC 1.7 (1.3, 2.2) 1.7 (1.3, 2.3) 1.1 (0.7, 1.5) 1.7 (1.1, 2.4) 1.4 (0.9, 2.3) 1.5 (1.0, 2.4)
ApoC-III Intron 1 G/C GG 1.9 (1.4, 2.5) 1.8 (1.3, 2.3) 1.4 (0.5, 3.9) 1.1 (0.5, 2.3) 1.1 (0.6, 1.8) 1.9 (1.2, 3.0)
GC/CC 1.7 (1.3, 2.3) 2.0 (1.5, 2.5) 1.0 (0.7, 1.5) 1.5 (1.1, 2.5) 1.5 (1.0, 2.4) 1.5 (0.9, 2.4)
ApoC-III Gly34Gly C/T CC 1.9 (1.5, 2.5) 1.8 (1.4, 2.3) 1.1 (0.7, 1.6) 1.5 (1.1, 2.2) 1.3 (0.8, 2.1) 1.9 (1.1, 3.0)
CT/TT 1.7 (1.3, 2.2) 1.8 (1.4, 2.4) 1.0 (0.6, 1.6) 1.5 (1.0, 2.2) 1.4 (0.9, 2.4) 1.6 (1.0, 2.5)
ApoC-III SstI (3238C/G) CC 1.8 (1.4, 2.3) 1.8 (1.4, 2.4) 1.1 (0.7, 1.6) 1.5 (1.1, 2.2) 1.2 (0.8, 1.9) 1.7 (1.1, 2.7)
CG/GG 1.7 (1.2, 2.5) 2.0 (1.4, 2.6) 1.0 (0.6, 1.7) 1.5 (1.0, 2.2) 1.5 (0.9, 2.6) 1.5 (0.9, 2.4)
ApoA-I XmnI( 2500C/T) CC 1.9 (1.5, 2.4) 1.9 (1.5, 2.4) 1.0 (0.7, 1.5) 1.4 (1.0, 2.1) 1.3 (0.8, 2.0) 1.9 (1.1, 3.0)
CT/TT 1.6 (1.1, 2.3) 1.7 (1.3, 2.2) 1.2 (0.8, 1.9) 1.7 (1.2, 2.5) 1.7 (0.9, 3.2) 1.6 (1.0, 2.6)
Models (as per Table 3) are fit separately for each SNP and adjusted for sex, study, age, CD4 count, use of lipid-lowering therapy, and ART drug exposure (indicators for stavudine, EFV, and NFV). Predictions are for a 41-y-old male with a CD4
count of 442 and not on a lipid-lowering therapy. These values are based on the median values observed for these variables in the entire cohort. Observations missing genotype information were excluded from corresponding model (n¼8f o r
apoC-III-482, n ¼ 5 for apoC-III-455, n ¼ 6 for apoC-III Intron 1, n ¼ 2 for apoC-III Gly34Gly, n ¼ 3 for apoC-III SstI [3238], and n ¼ 8 for apoA-I XmnI [-2500]).
DOI: 10.1371/journal.pmed.0030052.t005
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Ethnicity, ApoC-III, and Lipids in HIV[38] found an association of the 482T allele with increases in
metabolic parameters in Whites, but decreases in these
readouts in African-ancestry individuals.
Recent work has demonstrated a potential interaction of
lipoprotein genes with PI therapy in promoting lipid
abnormalities in HIV-1-infected patients. Fauvel et al. studied
60 consecutive, PI-treated (mostly indinavir) White males
with HIV-1, who were also taking two nucleoside reverse
transcriptase inhibitors, and found that the rare apoC-III
 455C,  482T, or SstI-S2(G) variants were associated with
higher TGs and apoB lipoproteins as well as lower HDL-c
[13]. Tarr et al. assessed the effect of apoE and apoC-III
genotypes on change in lipids on ART in HIV-1-infected
patients (n ¼ 329) [15]. They found that those patients on
RTV, who also had apoE variants (non e3/e3) and all three
 482T, 455C, and 3238G (SstI) apoC-III polymorphisms, had
marked increases in TG levels.
Both of these studies, predominantly of Whites, concluded
that the apoC-III-482 (CT and TT),  455 (TC and CC), and
3238 (SstI) (GC and GG) genotypes may be associated with
increased TG levels in HIV-1-infected patients on PIs. We did
not detect signiﬁcant interaction effects of these apoC-III
genotypes with PIs on plasma TGs in Whites. Despite this, our
ﬁndings are broadly consistent with these papers in that TG
levels in White and Blacks with these genotypes on PIs in our
study tended to be higher than individuals not on PI therapy;
however, the magnitude of effects on lipids were more
modest. These differences may reﬂect study design and
confounding variables including age, gender, concurrent
use and type of non-PI ART, the prevalence of diabetes,
and use of lipid-lowering medications. Furthermore, we did
not consider apoE or other candidate genes that might
further modify the association of PIs with dyslipidemia.
Notably, in Tarr et al. the interaction with PI therapy was only
signiﬁcant in those individuals with the combination of apoE
and apoC-III variants [15].
As hypothesized, we found evidence of race/ethnic differ-
ences in the association of apoC-III genotypes with PI-related
dyslipidemia as well as marked race/ethnicity speciﬁc differ-
ences in SNP and estimated haplotype frequencies. Although
Figure 2. Predicted TG Levels for PI- and Non-PI–Exposed Hispanics by Composite ApoC-III Genotype Variable
*ApoCIII-482 (CT/TT),  455 (TC/CC), and/or SstI (3238) CG/GG. The negative effect of PI exposure on TGs is greatly attenuated (56% less) among
Hispanics with one or more apoC-III variant compared to Hispanics with the wild-type genotype at these loci (95% CI ¼ [0.32, 0.97], p-value ¼ 0.04.)
DOI: 10.1371/journal.pmed.0030052.g002
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Ethnicity, ApoC-III, and Lipids in HIVour ﬁndings of a potential protective effect of the non-wild-
type apoC-III variants on PI-induced hypertriglyceridemia in
Hispanics is not consistent with studies in White samples,
they are not surprising in the context of prior studies that
demonstrated complex transcriptional regulation of the
apoA-I/CIII/AIV/AV gene cluster [55], race/ethnic speciﬁc
LD across this region [36–38], interplay of distinct alleles
that confer susceptibility/resistance to hypertriglyceridemia
[28,29,39,45,50], and prior evidence for modiﬁcation of apoC-
III effects by race/ethnicity [38,40]. Our ﬁnding does not
imply that ‘‘race’’ is responsible for speciﬁc differences in
SNP functional effects. Rather, it is much more likely that
differences relate to race/ethnicity-speciﬁc LD with unmeas-
ured functional variants in the apoA-I/C-III/AIV/AV cluster,
or to the confounding inﬂuence of additional environmental
or genetic factors which also vary with race/ethnicity. For
these reasons, we believe that our ﬁndings are not in conﬂict
with published studies including those in HIV-1 samples
[13,15].
Race/ethnicity is often considered a surrogate for environ-
mental inﬂuences on lipids, but recent studies demonstrate
that genetic factors also account for important differences in
plasma lipids across ethnic groups [34,56]. For example,
hepatic lipase SNPs, present only in African Americans, result
in lower enzyme activity and account for a signiﬁcant
proportion of the race/ethnic differences in HDL-c levels
[34]. Recently, Cohen et al. reported that loss-of-function
mutations in proprotein convertase subtilisin kexin-9, a gene
that regulates hepatic low density lipoprotein receptor
expression, were associated with markedly lower plasma
levels of low density lipoprotein and that these mutations
were relatively common in African Americans but rare in
European Americans [56]. In this context, it is likely that
genetic variation, as well as environmental factors, contribute
to signiﬁcant region-speciﬁc differences in lipid and meta-
bolic complications of ART, such as those noted in the
recently completed 2NN multi-national clinical trial [57].
The main limitation of our study is that it was cross-
sectional, involved a heterogeneous, multi-ethnic sample
across ACTG studies, and had limited power to detect small
interaction effects within race/ethnic strata. Our goal was to
characterize trends in the data, and we caution against
placing too much emphasis on the absolute p-values, since
type I errors due to multiple testing are possible with
subgroup analyses. Due to the highly correlated nature of
many of the reported tests, induced by the overlap in
genotypes across SNPs, we included an analysis of a single
composite genotype variable that is consistent with multi-
locus analysis approaches in the literature [13,15,58,59]. While
this approach is not a correction for multiple testing, it lends
strong support to the single SNP analysis and is an
appropriate alternative for our setting. Our ﬁndings require
further evaluation, ideally in large prospective cohort or
randomized trial settings that determine changes in lipids
over time and also allow a careful assessment of additional
environmental (e.g., diet and smoking) and genetic factors
(e.g., apoE and lipase genotypes). However, to date this is the
largest pharmacogenetic study in HIV-1 to address ethnic
variation in plasma lipoproteins in patients on ART.
Overall, our ﬁndings of race/ethnicity-speciﬁc apoC-III-PI
interaction on plasma TGs should be interpreted cautiously.
Based on an examination of 43 meta-analyses of genetic
association studies, Ioannidis et al. concluded that the
biological impact of genetic markers on risk for common
diseases is usually consistent across racial boundaries [60].
However, they did ﬁnd almost a 3-fold greater occurrence of
race-speciﬁc heterogeneity in genetic effects than would be
expected by chance. Thus, the challenge lies in identifying
which genetic effects may be inﬂuenced by race/ethnicity and
what is the basis of such inﬂuences. Our ﬁndings caution
against generalizing results of genetic studies in White
samples when considering metabolic traits in HIV-1 pop-
ulations, particularly for genes with known complex LD
structures reported to vary by race/ethnicity.
In summary, this study provides novel information regard-
ing HIV-1 subgroups that may be at differential risk of
developing metabolic and CV complications of ART. Ap-
proaches that account for racial/ethnic heterogeneity are
mandated in pharamcogenetic studies of such complications
given the multi-ethnic distribution of HIV-1 infection,
concerns regarding future atherosclerotic CV disease in
these populations, and the potential to use alternative
strategies [16,61] to reverse or avoid metabolic effects of ART.
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Patient Summary
Background. One of the unfortunate side effects of protease
inhibitors—one of the types of drugs used in treating HIV—is that they
affect lipids in the body; for example, they cause the level of triglycerides
to increase in such a way as to make it more likely that patients will
develop diseases associated with abnormal lipids such as heart disease
and stroke. As these drugs are taken for very long periods of time, there
are concerns that there may be a future epidemic of cardiovascular
disease in patients with HIV-1 who have taken such lifelong treatment.
Why Was This Study Done? The authors wanted to see if they could
identify individuals with HIV who are at increased risk of getting the lipid
abnormalities caused by these drugs; in particular, they wanted to see if
t h e r ew e r ed i f f e r e n c e sa c r o s sd i fferent racial/ethnic groups and
according to common variation in some lipid genes. Knowing about
such differences might help in deciding between the various different
drug treatments available.
What Did the Researchers Do and Find? They looked at 626 people
who had taken part in previous studies of HIV drugs, and who had
agreed to have their blood stored for further studies such as these. They
found that race/ethnicity could help predict levels of plasma lipids, and
that the effect of taking protease inhibitors also appeared to differ across
race/ethnicity groups. Overall, Black patients taking these drugs were
less likely to have the lipid profiles that lead to cardiovascular disease,
compared to Whites and Hispanics. However, individuals in all racial/
ethnic groups had increases in triglyceride levels when they were given
these drugs. Furthermore, Hispanics, but not Whites or Blacks, with
variation in the apoC-III gene, appeared to be protected from the
triglyceride-raising effect of protease inhibitors
What Do These Findings Mean? Given that HIV is a disease that affects
all racial/ethnic groups, it will be important in the future to study
carefully and in large numbers the patients of all racial/ethnic groups in
studies of metabolic and cardiovascular complications of drugs used to
treat HIV. It may also be necessary to look at the effect of certain genes
on these lipids. In the future it may be possible to use this information to
decide which patients should receive which drugs.
Where Can I Get More Information Online? AIDSinfo is a site run by
the National Institutes of Health in the US that has many pages of
information on HIV. Searching for ‘‘lipid’’ will bring up fact sheets on HIV
drugs and the type of lipid changes discussed in this article:
http://aidsinfo.nih.gov
TheBody.com is an HIV/AIDS resource that can be searched for
information on the effects of these drugs on lipids. One page to start
at is:
http://www.thebody.com/treat/cardiac.html
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